A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00002201
First received: November 2, 1999
Last updated: February 19, 2009
Last verified: February 2009

November 2, 1999
February 19, 2009
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002201 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.

The purpose of this study is to see if it is safe and effective to give ritonavir plus nelfinavir to HIV-infected patients. This study will also see how ritonavir and nelfinavir are absorbed by the body and how they affect the level of HIV in the blood.

Not Provided
Interventional
Not Provided
Endpoint Classification: Pharmacodynamics Study
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Ritonavir
  • Drug: Nelfinavir mesylate
Not Provided
Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):322-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Patients must have:

  • Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay.
  • HIV RNA measurement of > 5,000 copies/ml within 3 weeks of baseline visit.
  • Signed, informed consent from parent or legal guardian for patients less than 18 years of age.
  • Access to a refrigerator for storing study drug.

Prior Medication:

Allowed:

Anti-HIV therapy other than protease inhibitor therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Evidence of acute infection, as measured by vital signs, physical examination, 12-lead electrocardiogram and laboratory assessments.
  • Condition that may obscure the proper observation of the safety or activity of the treatment regimens.

Concurrent Medication:

Excluded:

  • Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil, terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine, propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin.
  • Anti-retroviral therapy initiated prior to study entry.
  • Any other medication, including over-the-counter medicine and alcohol, taken without the permission of the primary investigator.

Patients with the following prior conditions are excluded:

  • History of significant drug hypersensitivity.
  • History of psychiatric illness that would preclude compliance with the protocol.
  • Prior enrollment in this study.

Prior Medication:

Excluded:

  • Investigational drugs within 30 days prior to drug administration.
  • Prior treatment with licensed or investigational HIV protease inhibitor.

    1. Active substance abuse.

  • Positive urine screen for recreational drugs. NOTE:
  • The presence of cannabis is not exclusionary unless the investigator believes its use will interfere with patient compliance.
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002201
245D, M96-581
Not Provided
Not Provided
Abbott
Not Provided
Not Provided
Abbott
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP